Project Grant R37CA304546
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $736K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $723,547 on June 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to delineate the role of 5' untranslated regions in prostate cancer clonality. The research addresses the heterogeneity of prostate cancer within individual patients through investigation of how untranslated regions modulate clonal growth in prostate cancer cells. Preliminary work conducted an unbiased 5' UTR tiled...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,927,373.00 to the Fred Hutchinson Cancer Center in Seattle, WA to support the "Development of Targeted Therapies for Metastatic Prostate Cancers Classified by Subtypes of DNA Repair Deficiency". The 3-year project aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader...
- The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $760,396 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate metabolomic mechanisms contributing to prostate cancer risk across multiple populations. The research will generate circulating metabolomic data on 3,006 prostate cancer cases and 3,006 controls from Black, Hispanic, Japanese American, and White individuals enrolled in the Multiethnic...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $487,902 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct genome-wide association studies interrogating cancer pleiotropy and shared genetic susceptibility mechanisms across multiple cancer types. The project leverages existing genomic data from large biobanks including the UK Biobank and All of Us to identify shared germline susceptibility regions underlying cancer risk. The...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $525,847 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 15, 2025 through July 14, 2027. The award supports research to define and exploit essential components of the androgen receptor program operative in castration-resistant prostate cancers. This research addresses a critical health challenge affecting military...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $752,751 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decipher tumor heterogeneity, metastatic spread, and treatment resistance in advanced bladder cancer through the Fred Hutch/UW Bladder Cancer Rapid Autopsy Program. The project builds on an existing resource established in 2015 that collects tumors and matched benign tissues from metastatic bladder cancer patients within hours of death, with...
- This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the Fred Hutchinson Cancer Center in Seattle, WA to target epidermal plasticity to prevent triple negative breast cancer recurrence. The $1,173,081 award, with a performance period from April 1, 2025 to March 31, 2029, will fund cutting-edge biomedical research focused on developing innovative medical solutions to address...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $192,024 under the Cancer Research Manpower program (CFDA 93.398) on July 16, 2026, to support research on synthetic costimulation and signaling calibration for chimeric T cell receptors. The project, identified as K22CA303684, advances bispecific chimeric T cell receptor (BI-CHTCR) engineering to overcome limitations in current CAR T cell therapies for B cell malignancies. Existing CAR T cells frequently relapse due to...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $716,319 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize CD45-targeted astatine-211 radioimmunotherapy for malignant and non-malignant blood disorders. The funded work focuses on developing and refining astatine-211 (211AT) radioisotope-conjugated monoclonal antibodies targeting CD45, an antigen expressed on hematopoietic cells. The research builds on prior Phase 3 trial validation of...